Verastem Oncology has secured orphan drug designation for COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K), from the US Food and Drug Administration (FDA) for the treatment of T-Cell lymphoma. COPIKTRA has FDA approval for th…
Amylyx Pharmaceuticals said that the last enrolled patient in the CENTAUR clinical trial, which is evaluating AMX0035 for amyotrophic lateral sclerosis (ALS), has finished the 24 weeks of study treatment. The CENTAUR clinical study is a randomized, dou…
AstraZeneca has bagged approval from the US Food and Drug Administration (FDA) for the self-administration of FASENRA (benralizumab) through FASENRA Pen, a pre-filled, single-use auto-injector, for the add-on maintenance treatment of severe asthma in p…
Icosavax, a new pharma company, focused on developing vaccines against infectious diseases, has been launched in Seattle, Washington. The vaccine development company is backed by $51 million capital raised through a Series A financing round led by Qimi…
Graybug Vision has initiated the ALTISSIMO clinical trial, a phase 2b study, which will evaluate its pan-VEGF receptor inhibitor GB-102 in patients with wet age-related macular degeneration (wet AMD). Based in California, Graybug Vision is a clinical-s…
US immuno-oncology company Elicio Therapeutics has raised $33 million through a Series B financing round to advance ELI-002, an Amphiphile mKRAS vaccine (AMP KRAS), and other lymph node targeted immuno-therapies. Elicio Therapeutics said that it has es…
Checkmate Pharmaceuticals announced the dosing of the first patient in a phase 1b/2 study of BAVENCIO (avelumab) in multi-drug combinations with its lead candidate CMP-001 in patients having squamous cell cancer of the head and neck (SCCHN), as part of the JAVELIN Medley trial. CMP‐001 is a C0pG‐A Toll‐like receptor 9 (TLR9) agonist that is […]
The post JAVELIN Medley trial : First patient dosed with BAVENCIO, CMP-001 combo appeared first on PharmaNewsDaily.com.
Meissa Vaccines, a US biotech company focused on developing vaccines for the prevention of viral respiratory infections, has raised $30 million in a Series A financing with Morningside Ventures. The US biotech company plans to use the new capital for the expansion of its team, for undertaking phase 1 and 2 clinical trials for its […]
The post Meissa Vaccines raises $30m to move RSV Vaccine into clinical trials appeared first on PharmaNewsDaily.com.
US biotech company Progenity has acquired patented assets of Medimetrics, a Dutch ingestible device company, for an undisclosed price. The acquired portfolio for ingestible device technologies includes 137 granted patents to go along with 15 pending applications in the US, Europe, Japan, and China. The Medimetrics assets will further consolidate Progenity’s intellectual property portfolio. Furthermore, […]
The post Progenity buys assets of ingestible device company Medimetrics appeared first on PharmaNewsDaily.com.
Rybelsus FDA approval : Danish pharma company Novo Nordisk has bagged approval from the US Food and Drug Administration (FDA) for Rybelsus (semaglutide) oral tablets for its use in patients with type 2 diabetes. The FDA approval for Rybelsus is to improve control of blood sugar in addition to diet and exercise in adults having […]
The post Novo Nordisk bags Rybelsus FDA approval for type 2 diabetes appeared first on PharmaNewsDaily.com.